AstraZeneca forged a new and unique model to drive neuroscience innovation – the Neuroscience Innovative Medicines Unit, or Neuroscience IMED. This bold approach to neuroscience drug discovery research and development was designed to address the significant challenges the pharmaceutical industry faces in bringing new medicines to market.
While many companies have reduced their investments in the neuroscience arena, AstraZeneca continues to be committed to addressing the critical patient need for new treatments. In fact, recent scientific advances in this area are groundbreaking and could transform the neuroscience landscape – the Neuroscience IMED is poised to capture and build upon this momentum. Collaboration is at the core of everything we do.
The Neuroscience IMED model is unique in that it is dynamic and fully externalised. Instead of operating its own labs in-house, the IMED is forming partnerships with leading edge academic researchers, foundations and companies to create a portfolio of discovery and early development projects with the ultimate goal of working together to develop new breakthrough medicines for patients with neurological disorders or disease. This model balances the extensive resources and capabilities of AstraZeneca and its global biologics research and development arm, MedImmune, with the flexible, fast-moving and nimble Neuroscience IMED focused on rapidly advancing new and exciting projects from target identification to Proof of Concept studies.